This is a clinical-stage biopharmaceutical company working on creating a new kind of antibiotics. These antibiotics are specifically designed to combat infections caused by bacteria that are considered high-priority threats by organisations like the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). Acurx Pharmaceuticals focuses on developing antibiotics that target the DNA polymerase IIIC enzyme (Pol IIIC), a key player in the DNA replication process in Gram-positive bacterial cells. The company's research and development pipeline includes antibiotic candidates in various stages that aim to treat infections caused by specific bacteria strains, including Clostridium difficile, vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus and antibiotic-resistant Streptococcus.